Opexa Therapeutics (OPXA) Misses Q3 EPS by 3c

Opexa Therapeutics (NASDAQ: OPXA) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $726.3 thousand versus the consensus estimate of $720 thousand.

Cash and cash equivalents were $5,814,300 as of September 30, 2016, compared to $12,583,764 as of December 31, 2015. As of September 30, 2016, the Company had accounts payable and accrued expenses of $2,121,043.

For earnings history and earnings-related data on Opexa Therapeutics (OPXA) click here.

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• StoneX Reiterates Buy Rating on Marcus Corp. (MCS)
• Alibaba ADR climbs on analyst upgrades, AI momentum